Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 6/20 | 0.65 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL230368 | 0.87 | HSP90AB1 (0.82) | HSP90AB1CYP19A1NPC1RAB9AHRH4 | |
| SCHEMBL30959784 | 0.86 | HSP90AB1 (0.80) | HSP90AB1CYP19A1NPC1RAB9AHRH4 | |
| SCHEMBL21293881 | 0.86 | HSP90AB1 (0.80) | HSP90AB1CYP19A1NPC1RAB9AHRH4 | |
| SCHEMBL29661913 | 0.80 | CNR2 (0.40) | HSP90AB1 | |
| SCHEMBL18028297 | 0.80 | HSP90AB1 (0.70) | HSP90AB1CYP19A1NPC1RAB9A | |
| SCHEMBL10044915 | 0.79 | HSP90AB1 (0.69) | HSP90AB1CYP19A1NPC1RAB9AHRH4 | |
| Sulfuric Acid SCHEMBL28657977 | 0.78 | HSP90AB1 (0.68) | HSP90AB1CYP19A1NPC1RAB9AHRH4 | |
| SCHEMBL15796690 | 0.78 | HDAC1 (0.55) | HSP90AB1CYP19A1NPC1RAB9AHRH4 | |
| SCHEMBL15425743 | 0.77 | CYP19A1 (0.67) | HSP90AB1CYP19A1NPC1RAB9AHRH4 | |
| SCHEMBL17104470 | 0.77 | CYP19A1 (0.67) | HSP90AB1CYP19A1NPC1RAB9AHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117377759-A | Self-purified nucleic acid-encoded libraries | 约尔格·谢尔曼 | 2024-01-09 | — | — | CN | disclosed |
| WO-2023154314-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20210107859-A1 | A PROCESS FOR THE SYNTHESIS OF CARBON LABELED ORGANIC COMPOUNDS | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2021-04-15 | — | — | US | disclosed |
| US-20120245040-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | GLAXOSMITHKLINE (US) | 2012-09-27 | — | — | US | disclosed |
| EP-2452936-A1 | Compositions and methods for coupling a plurality of compounds to a scaffold | The Scripps Research Institute (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20120071329-A1 | METHODS FOR IDENTIFYING COMPOUNDS OF INTEREST USING ENCODED LIBRARIES | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | US | disclosed |
| US-7989395-B2 | Methods for identifying compounds of interest using encoded libraries | GLAXOSMITHKLINE LLC (US) | 2011-08-02 | — | — | US | disclosed |
| US-7972994-B2 | Methods for synthesis of encoded libraries | GLAXOSMITHKLINE LLC (US) | 2011-07-05 | — | — | US | disclosed |
| US-20110136697-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2011-06-09 | — | — | US | disclosed |
| US-7935658-B2 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20090062147-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2009-03-05 | — | — | US | disclosed |
| US-20070224607-A1 | Methods for identifying compounds of interest using encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2007-09-27 | — | — | US | disclosed |
| WO-2007053358-A2 | METHODS FOR IDENTIFYING COMPOUNDS OF INTEREST USING ENCODED LIBRARIES | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070042401-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007011696-A2 | COMPOSITIONS AND METHODS FOR COUPLING A PLURALITY OF COMPOUNDS TO A SCAFFOLD | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245040-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | RNGTT, DTYMK, DUT | HSP90AB1 1018/4885CYP19A1 3388/4885NPC1 1992/4885 |
| US-20210107859-A1 | A PROCESS FOR THE SYNTHESIS OF CARBON LABELED ORGANIC COMPOUNDS | OTC, MCCC2, CPS1 | HSP90AB1 3866/4885CYP19A1 401/4885NPC1 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.